Skip to main navigation Skip to search Skip to main content

Abstract

During the last decade, enzyme replacement therapy for lysosomal storage diseases became a reality with the demonstration of its safety and effectiveness in type 1 Gaucher disease. Currently, enzyme replacement and several other potential therapeutic strategies are being developed for selected lysosomal storage diseases, including Fabry disease due to the deficient activity of α-galactosidase A (α-Gal A). The development and clinical evaluation of these new therapies require a stepwise process, each step being rigorously reviewed and approved by national or international regulatory agencies. For lethal disorders that affect small populations, such as many inherited metabolic diseases, this process can be accelerated by 'orphan drug' and 'fast track' regulations. As an example of the drug development process, the development of recombinant human α-Gal A (r-hαGal A) replacement for Fabry disease is presented, including the preclinical studies in the 'Fabry mouse' model, and the clinical phase 1/2, phase 3, and phase 3 extension studies, which demonstrate the safety and efficacy of this new therapy.

Original languageEnglish
Pages (from-to)251-265
Number of pages15
JournalJournal of Inherited Metabolic Disease
Volume24
Issue number2
DOIs
StatePublished - 2001

Fingerprint

Dive into the research topics of 'Enzyme replacement and beyond'. Together they form a unique fingerprint.

Cite this